8:00 am

Welcome and audience survey
Morton Coleman, MD

8:05 am

Introduction to Myeloma Session
Ruben Niesvizky, MD

8:10 am

Understanding the genetics and epigenetics of myeloma and their therapeutic potential
Faith E. Davies, MBBBch, MD, MRCP, FRCPath

8:30 am

Understanding the cell cycle of myeloma and the therapeutic opportunities
Selina Chen-Kiang, MD

8:50 am

Understanding the biologic pathways in myeloma and their therapeutic implications
Constantine S. Mitsiades, MD, PhD

9:10 am

Panel discussion and questions

9:25 am

Coffee break

9:45 am

Pre-session audience survey

9:55 am

The biology of bone disease: How important are “markers”?
Noopur S. Raje, MD

10:15 am

A role of denosumab and other new agents in myeloma
James E. Berenson, MD

10:35 am

Imaging techniques in myeloma: How best to use them
Meletios-Athanasios Dimopoulos, MD

10:55 am

Post-session audience survey

11:05 am

Panel discussion and questions

11:20 am

Break for lunch symposium:
How I Manage Distinct Clinical Scenarios Across Lymphoma: A Case-Based, Rapid Fire Panel Discussion

1:20 pm

Pre-session audience survey

1:30 pm

“High-risk” myeloma: Definition and treatment
Rafael Fonseca, MD

1:50 pm

Plasma cell leukemia: Should it be treated differently?
Joan Bladé, MD

2:10 pm

If and when should an allogeneic transplant be done?
Sergio A. Giralt, MD

2:30 pm

Post-session audience survey

2:40 pm

Panel discussion and questions

2:55 pm

Coffee break

3:15 pm

Presentation of the best myeloma abstract

3:25 pm

The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Recipient: Brian G. M. Durie, MD

3:30 pm

“Consensus” on the standards of treatment in the 21st century: How should we treat transplant-eligible, transplant-ineligible, and relapsed patients
Brian G. M. Durie, MD

3:55 pm

Pre-debate audience survey
Debate: Is maintenance therapy necessary?
Yes: Antonio Palambo, MD
No: David Vesole, MD
Post-debate audience survey

4:35 pm

Panel discussion and questions

4:50 pm

Adjourn for abstract reception

8:00 am

Welcome and audience survey
Morton Coleman, MD

8:05 am

Pre-debate audience survey
Debate: Are transplants necessary as frontline therapy?
Yes: Bart Barlogie, MD, PhD
No: Sundar Jagannath, MD
Post-debate audience survey

8:45 am

Panel discussion and questions

9:00 am

Coffee break

9:30 am

Carfilzomib
Ruben Niesvizky, MD

9:50 am

Pomalidomide
Tomer Mark, MD

10:10 am

Elotuzumab
Paul G. Richardson, MD

10:30 am

HDAC inhibitors
Kenneth C. Anderson MD

10:50 am

Bendamustine
Suzanne Lentzsch, MD, PhD

11:10 am

Break for lunch symposium:
Prolonging Survival in Multiple Myeloma: Balancing the Efficacy of Maintenance Therapy with Long-Term Safety A Case-Based, Roundtable Discussion

1:10 pm

Introduction to CLL Session
Richard Furman, MD

1:15 pm

Pre-session audience survey

1:25 pm

Introduction to The Prince Family Lecture
Presenters: Morton Coleman, MD and Richard Furman, MD

1:30 pm

The Prince Family lecture: Is a cure on the horizon?
Michael J. Keating, MD

1:55 pm

Molecular pathogenesis and therapy of CLL
Thomas J. Kipps, MD, PhD

2:15 pm

Transplantation in CLL: How major a role?
Edwin Alyea, MD

2:35 pm

Post-session audience survey

2:45 pm

Panel discussion and questions

3:00 pm

Coffee break

3:20 pm

Pre-session audience survey

3:30 pm

Treatment of the elderly: How gentle should it be?
Neil E. Kay, MD

3:50 pm

Non-chemotherapeutic approaches: Can we avoid alkylators and purine analogues?
Susan O’Brien, MD

4:10 pm

Novel approaches to CLL: Exciting new agents
Richard Furman, MD

4:30 pm

Post-session audience survey

4:40 pm

Panel discussion and questions

4:55 pm

Adjourn

8:00 am

Welcome and audience survey
Morton Coleman, MD

8:05 am

Introduction to Lymphoma Session
John P. Leonard, MD

8:10 am

New molecular targets in large cell lymphoma
Lisa M. Rimsza, MD

8:25 am

BCL-6: a regulator of lymphomagenesis
Ari Melnick, MD

8:40 am

Panel discussion and questions

8:50 am

Limited treatment for limited disease?
Volker Diehl, MD

9:10 am

Emerging new agents in Hodgkin’s and lymphoma
Jonathan Friedberg, MD

9:30 am

Is there a role for consolidation radiation in limited and advanced Hodgkin’s disease in the era of PET scan?
Peter Johnson, MD

9:50 am

Panel discussion and questions

10:05 am

Coffee break

10:25 am

Presentation of best lymphoma abstract

10:35 am

The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for Contributions to Lymphoma Research
Presenters: Morton Coleman, MD and John P. Leonard, MD
Recipient: Bertrand Coiffier, MD

10:40 am

Is R-CHOP-21 still the standard for all patients or is there a role for CHOP-14, ABVCP, EPOCH, etc?
Bertrand Coiffier, MD

11:00 am

The Bruce Waterfall Memorial Lecture in Waldenstrom’s Macroglobulinemia
Presenter: Morton Coleman, Md
Moderator: Peter Martin, MD

Treatment approaches for untreated and relapsed disease
Stephen M. Ansell, MD, PhD

11:25 am

Panel discussion and questions

11:40 am

Break for lunch

1:40 pm

Pre-debate audience survey
Debate: Should everyone receive maintenance rituximab?
Yes: David Maloney, MD, PhD
No: Bruce E. Cheson, MD
Post-debate audience survey

2:20 pm

Pre-debate audience survey
Debate: Is “watch and wait” passé in asymptomatic follicular lymphoma?
Yes: John P. Leonard, MD
No: Myron Czuczman, MD
Post-debate audience survey

3:00 pm

Panel discussion and questions

3:15 pm

Pre-session audience survey

3:25 pm

Relapsed aggressive lymphoma: what approaches are applicable for transplant eligible and ineligible patients? What has the CORAL study taught us?
Craig Moskowitz, MD

3:45 pm

Mantle cell lymphoma: How best to approach and treatment: Is there a role for maintenance?
Brad Kahl, MD

4:05 pm

Double hit aggressive lymphoma
Kieron Dunleavy, MD

4:25 pm

Pre-session audience survey

4:35 pm

Panel discussion and questions

4:50 pm

Adjourn